PURPOSE: Preoperative findings, pathological stage PSA recurrence in patients with prostate cancer incidentally detected (iPCa) at radical cystectomy (RCP) were prospectively evaluated. METHODS: From July 2000 to July 2013, 242 men 71 years old (median) underwent RCP; preoperatively, all patients underwent digital rectal examination (DRE), total and free/total PSA. The bladder was totally examined; moreover, the prostate gland was step-sectioned at 4-mm intervals. The incidence of iPCa that fulfilled criteria for clinically significant iPCa was recorded: tumor volume ≥0.5 mL, Gleason grade ≥4, extracapsular extension, seminal vesicle invasion, lymph node metastasis or positive surgical margins. In the presence of iPCa, the patients underwent PSA evaluation during the follow-up and recurrence was defined as two subsequent rises >0.2 ng/mL. RESULTS: Among the 50 (20.6%) out of 242 patients submitted to RCP, an iPCa was found and 18 (36%) of them met criteria for insignificant iPCa; moreover, 30% of the patients had apex involvement. Median total PSA and PSA F/T values were not significantly different in the presence versus the absence of iPCa (2.6 vs 2.7 ng/mL and 26 vs 27%; p > 0.05) and between significant versus insignificant iPCa (p > 0.05). None of the patients during the follow-up (median 58 months; range 6-102 months) had PSA recurrence. CONCLUSIONS: PSA and PSA F/T values are provided for poor accuracy in distinguishing preoperatively significant from insignificant iPCa; however, the life expectancy of the patients is dramatically influenced by bladder cancer pTN (in our series, none developed PSA failure). In younger men in whom a prostate-sparing cystectomy could be proposed, an accurate preoperative evaluation should be mandatory to rule out significant iPCa at the risk of apex involvement (in our series equal to 30% of the cases).
PURPOSE: Preoperative findings, pathological stage PSA recurrence in patients with prostate cancer incidentally detected (iPCa) at radical cystectomy (RCP) were prospectively evaluated. METHODS: From July 2000 to July 2013, 242 men 71 years old (median) underwent RCP; preoperatively, all patients underwent digital rectal examination (DRE), total and free/total PSA. The bladder was totally examined; moreover, the prostate gland was step-sectioned at 4-mm intervals. The incidence of iPCa that fulfilled criteria for clinically significant iPCa was recorded: tumor volume ≥0.5 mL, Gleason grade ≥4, extracapsular extension, seminal vesicle invasion, lymph node metastasis or positive surgical margins. In the presence of iPCa, the patients underwent PSA evaluation during the follow-up and recurrence was defined as two subsequent rises >0.2 ng/mL. RESULTS: Among the 50 (20.6%) out of 242 patients submitted to RCP, an iPCa was found and 18 (36%) of them met criteria for insignificant iPCa; moreover, 30% of the patients had apex involvement. Median total PSA and PSA F/T values were not significantly different in the presence versus the absence of iPCa (2.6 vs 2.7 ng/mL and 26 vs 27%; p > 0.05) and between significant versus insignificant iPCa (p > 0.05). None of the patients during the follow-up (median 58 months; range 6-102 months) had PSA recurrence. CONCLUSIONS: PSA and PSA F/T values are provided for poor accuracy in distinguishing preoperatively significant from insignificant iPCa; however, the life expectancy of the patients is dramatically influenced by bladder cancerpTN (in our series, none developed PSA failure). In younger men in whom a prostate-sparing cystectomy could be proposed, an accurate preoperative evaluation should be mandatory to rule out significant iPCa at the risk of apex involvement (in our series equal to 30% of the cases).
Authors: L Cindolo; G Benincasa; R Autorino; S Domizio; G De Rosa; G Testa; M D'Armiento; V Altieri Journal: Oncol Rep Date: 2001 Mar-Apr Impact factor: 3.906
Authors: D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Roberta Mazzucchelli; Francesca Barbisan; Marina Scarpelli; Antonio Lopez-Beltran; Theodorus H van der Kwast; Liang Cheng; Rodolfo Montironi Journal: Am J Clin Pathol Date: 2009-02 Impact factor: 2.493
Authors: Hugo H Davila; Timothy Weber; David Burday; Scott Thurman; Rafael Carrion; Raoul Salup; Jorge L Lockhart Journal: BJU Int Date: 2007-09-14 Impact factor: 5.588
Authors: Pierre Nevoux; Adil Ouzzane; Hashim U Ahmed; Mark Emberton; Rodolfo Montironi; Joseph C Presti; Arnauld Villers Journal: BJU Int Date: 2011-12-22 Impact factor: 5.588
Authors: Antonio Lopez-Beltran; Liang Cheng; Francesco Montorsi; Maria Scarpelli; Maria R Raspollini; Rodolfo Montironi Journal: Nat Rev Urol Date: 2017-08-16 Impact factor: 14.432
Authors: Christian Thomas; Alexander Giesswein; Michael Hainz; Raimund Stein; Peter Rubenwolf; Frederik C Roos; Andreas Neisius; Sebastian Nestler; Christian Hampel; Wolfgang Jäger; Christoph Wiesner; Joachim W Thüroff Journal: Int Urol Nephrol Date: 2015-09-16 Impact factor: 2.370